Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Jaypirca
Pharma
Why Lilly is betting on 2nd-line CLL despite 1st-line wins
Lilly is defying the typical earlier-is-better strategy of cancer drug commercialization.
Angus Liu
Dec 9, 2025 7:30am
Lilly's BTK inhibitor Jaypirca wins lymphoma label expansion
Dec 3, 2025 8:25am
Trial results show value of Lilly's Jaypirca in front-line CLL
Sep 8, 2025 11:37am
BeOne widens BTK lead over AstraZeneca
Aug 6, 2025 10:55am
Lilly's BTK Jaypirca makes the grade versus Imbruvica
Jul 29, 2025 4:56pm
CHMP again backs Leqembi amid flurry of approval recommendations
Feb 28, 2025 10:30am
